A Phase 1, Randomized, Open Label, Single Dose, 2-period Crossover Study To Evaluate Food Effect On The Pharmacokinetics Of Pf-04136309 In Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Apr 2018
At a glance
- Drugs PF 4136309 (Primary)
- Indications Pancreatic cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 25 May 2016 Status changed from recruiting to completed.
- 14 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2016.
- 14 Apr 2016 Planned primary completion date changed from 1 Apr 2016 to 1 May 2016.